$VCEL

Mara Joseph Anthony Jr sold $224K of VCEL

Mara Joseph Anthony Jr (Chief Financial Officer) sold 5,000 shares of Vericel Corp (VCEL) at $44.75 ($0.22M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mara Joseph Anthony Jr
Published Jun 30, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCEL
Neutral
medium confidence
Mentioned
$VCEL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCELNeutralLow
01

Why it matters

The only new fact is the size, price, and timing of the CFO’s open-market sale under a pre-arranged 10b5-1 plan; no new company fundamentals are disclosed.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The filing date (2026-06-30) may not align with market reaction; the sale occurred 2026-06-26, so any immediate price effect would likely be limited.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-30 after-hours; reflects sale executed 2026-06-26.

Background

This is an SEC Form 4 insider transaction disclosure for Vericel Corp (VCEL) by its CFO.

Company-level read

Ticker impact

$VCELNeutralMedium confidence
Context

Vericel CFO Mara Joseph Anthony Jr filed a Form 4 selling 5,000 shares at $44.75 on 2026-06-26 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The disclosure is a scheduled open-market sale by the CFO with a pre-arranged 10b5-1 plan; no new operational, financial, or regulatory information is provided.

Market effects

Minimal; insider-sale filings typically do not reset sector expectations for biotech unless tied to new guidance or events (not present here).

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • Vericel Corp

    Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.

  • Mara Joseph Anthony Jr

    Chief Financial Officer who reported the sale of 5,000 shares.

Related articles

$VCELMedAI 8/10

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.

$VCELHigh

Vericel Corp (VCEL): Results of Operations and Financial Condition

Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Sh